Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes
- PMID: 30804691
- PMCID: PMC6372855
- DOI: 10.2147/PROM.S163601
Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes
Abstract
The systemic vasculitides are a group of multisystem diseases, which can be life and organ threatening. High-dose immunosuppressants are required to control inflammation in vital organs, such as the kidneys, lungs, skin, joints, and eyes. Patients report a range of impacts on their health-related quality of life due to symptoms, irreversible damage, and the adverse effects of medications. The measurement of patient perspectives within clinical studies in vasculitis is essential to capture outcomes of greatest importance to patients. Validated generic, disease-specific and symptom-specific patient-reported outcomes available for use in patients with systemic vasculitis are reviewed here.
Keywords: ANCA-associated vasculitis; Behcet’s syndrome; clinical trials; large-vessel vasculitis; patient-related outcomes; vasculitis.
Conflict of interest statement
Disclosure JCR, PAM, and JD developed the AAV-PRO. The authors report no other conflicts of interests in this work.
References
-
- Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford) 2011;50(4):697–702. - PubMed
-
- Robson J, Doll H, Suppiah R, et al. Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–184. - PubMed
-
- Nazareth R, Mason JC. Takayasu arteritis: severe consequences of delayed diagnosis. QJM. 2011;104(9):797–800. - PubMed
-
- Jones RB, Tervaert JW, Hauser T, et al. European Vasculitis Study Group Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–220. - PubMed
-
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
